+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Specific Imaging of Dialysis-Related Amyloid Deposits Using 131I-Beta-2-Microglobulin

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Dialysis-related amyloidosis (DRA), characterized by its association with β<sub>2</sub>-microglobulin (β<sub>2</sub>m), has become a major concern in long-term hemodialysis patients. Hitherto the diagnosis was based on histological examinations of tissue obtained by biopsy or during surgery. In this preliminary study a new noninvasive diagnostic method was developed using the affinity of β<sub>2</sub>m for its derived fibrils. 3 patients on long-term hemodialysis for 10–16 years with biopsy-proven DRA and 1 patient on chronic hemodialysis for only 6 months were examined after intravenous injection of <sup>131</sup>I-labelled β<sub>2</sub>m. Specific local accumulation of radioactivity was noted in the DRA patients after 48 h, persisting for further 96 h and corresponding to clinically or radiologically evident sites of amyloid deposition and to several other hitherto unsuspected sites. Examination of an excised amyloid tumor subsequent to in vivo labelling confirmed a highly specific accumulation of radioactivity in the amyloid tissue but not in control tissue. In the patient on chronic hemodialysis for only 6 months, no specific local accumulation was detected even after 1 week. These findings provide in vivo evidence in man that a specific uptake of circulating amyloid precursor molecules into deposits occurs and that this uptake may be used to radiolabel even small tissue infiltrates of amyloid. This method therefore may not only allow an objective, noninvasive detection of DRA but may also be used to obtain new pathophysiologic insights into amyloid formation in man, as well as permitting the evaluation of preventive therapeutic strategies in prospective studies on new patients.

          Related collections

          Author and article information

          S. Karger AG
          09 December 2008
          : 51
          : 3
          : 444-447
          Departments of aNephrology and bNuclear Medicine, Medizinische Hochschule Hannover, FRG; cDepartment of Pathology, Krankenhaus Nordstadt, Hannover, FRG; dAKZO Research Laboratory, Obernburg FRG, and eUniversity Hospital, Nîmes, France
          185351 Nephron 1989;51:444–447
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 4
          Rapid Communication

          Cardiovascular Medicine, Nephrology

          Hemofiltration, β2-Microglobulin, Hemodialysis, Amyloidosis


          Comment on this article